# Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

> **NCT04944368** · PHASE2 · COMPLETED · sponsor: **Cinnagen** · enrollment: 400 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant
- **BIOLOGICAL:** Saline placebo

## Key facts

- **NCT ID:** NCT04944368
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-30
- **Primary completion:** 2021-07-19
- **Final completion:** 2021-12-30
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2022-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04944368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04944368, "Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT04944368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*